Celldex started by Goldman Sachs at neutral, lack of catalysts cited

peterschreiber.media Celldex Therapeutics' ( NASDAQ: CLDX ) coverage was initiated at neutral by Goldman Sachs, due in part to concerns about the market opportunity for its drug candidate barzolvolimab in chronic urticaria and a lack of meaningful near-term catalysts. The investment bank said “strong statistical.